We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current TRX market cap is 43.05M. The company's latest EPS is USD -0.0043 and P/E is -141.86.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | USD ($) | GBP (£) | USD ($) | |
| Total Revenue | 13.03M | 12.83M | 19.75M | 24.48M | 29.49M |
| Operating Income | -7.2M | -9.75M | -4.46M | -2.03M | 1.03M |
| Net Income | -6.97M | -9.71M | -4.79M | -2.7M | -302k |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | USD ($) | GBP (£) | USD ($) | |
| Total Assets | 30.5M | 36.73M | 46.22M | 46.04M | 43.24M |
| Total Liabilities | 5.9M | 8.88M | 12.83M | 15.64M | 13.89M |
| Total Equity | 24.6M | 27.85M | 33.39M | 30.4M | 29.36M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | USD ($) | GBP (£) | USD ($) | |
| Operating | -6.68M | -5.23M | -2.98M | -1.29M | 1.04M |
| Investing | -634k | -1.37M | -2.04M | -1.08M | -837k |
| Financing | 1.9M | 13.77M | -192k | 910k | -1.51M |
| Market Cap | 43.05M |
| Price to Earnings Ratio | -141.86 |
| Price to Sales Ratio | 1.46 |
| Price to Cash Ratio | 9.26 |
| Price to Book Ratio | 1.47 |
| Dividend Yield | - |
| Shares Outstanding | 70.57M |
| Average Volume (1 week) | 39.78k |
| Average Volume (1 Month) | 68.19k |
| 52 Week Change | 8.93% |
| 52 Week High | 74.00 |
| 52 Week Low | 50.50 |
| Spread (Intraday) | 2 (3.23%) |
| Company Name | Tissue Regenix Group Plc |
| Address |
unit 3 leeds LS25 2GY |
| Website | https://www.tissueregenix.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
